Comparison of effect of Marma Therapy And Mukta Vati In in Stage I Hypertensio
Phase 3
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2020/06/025898
- Lead Sponsor
- Patanjali Research Institute Haridwar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Subjects will be enrolled with stage I HTN.
Subjects who are drug-naïve will be enrolled for the study with normal LV function.
Exclusion Criteria
LVEF < 50%
CKD, Serum creatinine > 1.7
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ambulatory BP (24 hr BP) <br/ ><br> <br/ ><br>Biochemical markers: <br/ ><br>Lipid profile <br/ ><br>Fasting glucose <br/ ><br>HbA1C <br/ ><br>Serum K+ <br/ ><br>Proteinuria <br/ ><br>LFT <br/ ><br>KFT <br/ ><br>Hs-CRP <br/ ><br>Serum cortisol <br/ ><br>Serum Insulin level <br/ ><br> <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: every week <br/ ><br>0-3months
- Secondary Outcome Measures
Name Time Method BPTimepoint: 0-3 months